First Patient Dosed in NefIgArd Open Label Extension Study
News provided by
Share this article
STOCKHOLM, Feb. 4, 2021 /PRNewswire/
Calliditas Therapeutics AB (publ) ( Calliditas ) today announced that the first patient has been dosed in the global open-label extension (OLE) of the Phase 3 NefIgArd study. OLE offers a 9-month treatment with Nefecon to all qualifying patients who have completed the NefIgArd study and will evaluate the efficacy and safety of Nefecon treatment in patients with IgA Nephropathy (IgAN).
This study will evaluate patients who have completed the Phase 3 study NefIgArd, which achieved both its primary and key secondary endpoints in the Part A topline data read out on November 8, 2020. All patients will continue on RAS inhibitor therapy (ACEs and/or ARBs) and be treated for 9 months with Nefecon in the OLE study.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Eastern Bank Earns 100 For 8th Consecutive Year in Human Rights Campaign Foundation’s 2021 Corporate Equality Index
February 4, 2021 GMT
For the eighth consecutive year,
Eastern Bank, including its Eastern Insurance Group subsidiary, is pleased to announce that it received a score of 100 on the Human Rights Campaign Foundation’s 2021 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality. Eastern joins 767 major U.S. businesses that also earned top marks this year, including 48 Massachusetts-based companies.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Semtech’s AVX Selected by Cypress Technology for Its AV Extenders
February 3, 2021 GMT
Cypress leverages Semtech s AVX technology (Photo: Business Wire)
CAMARILLO, Calif. (BUSINESS WIRE) Feb 3, 2021
Semtech Corporation (Nasdaq: SMTC), a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms, announced that Cypress Technology, a leader in design and manufacturing of innovative audio visual (AV) and multimedia products, has adopted Semtech’s AVX for its new line of high quality point-to-point AV extenders. Cypress selected AVX to enable transmission of uncompressed 4K60 video over distances up to 30km.
Sana Announces Upsized Pricing of Initial Public Offering
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a public offering price of $25.00 per share. All of the shares of common stock are being offered by Sana. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sana, are expected to be $587.5 million. Sana’s common stock is expected to begin trading on The Nasdaq Global Select Market on February 4, 2021, under the ticker symbol “SANA.” The offering is expected to close on February 8, 2021, subject to the satisfaction of customary closing conditions. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3,525,000 shares of common s
Sana Raises $588 Million in IPO to Advance Engineered Cell Therapies
Share
Rare Daily Staff
Sana Biotechnology, which made a splash in June 2020 when it emerged with $700 million in venture financing and a focus on creating and delivering engineered cells as medicines, is making another splash as its completes the largest initial public offering of a preclinical biotech company and putting its market capitalization at $4.9 billion.
Sana priced an upsized initial public offering of 23.5 million shares of its common stock at $25.00 per share, well above its initial target range of $20 to $23 a share. Sana’s will begin trading on The Nasdaq Global Select Market under the ticker symbol “SANA.” In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3.5 million shares of common stock at the initial public offering price, less the underwriting discounts and commissions, and, if exercised in full, would result in aggregate gro